Patients with asthma
Patients with asthma
are at an increased risk when using this medicine. Patients with asthma may have experience aspirin-sensitive asthma. The use of aspirin and other NSAIDs
in these patients may cause a fatal difficulty in breathing (bronchospasm). Take the necessary precautions while using this medicine in asthmatic patients. The Meloxicam should not be used in patients with aspirin sensitivity.
Patients receiving Meloxicam therapy are at an increased risk. Patients receiving Meloxicam therapy may experience anemia
, and this may be due to excess fluid build up in the body, stomach or intestinal blood loss, or an incomplete production of red blood cells (erythropoiesis). If signs or symptoms of anemia occur while using long-term therapy of Meloxicam, proper monitoring of blood levels (hemoglobin or hematocrit) should be done.
Life-threatening allergic reaction (anaphylactoid reactions)
Patients receiving Meloxicam therapy are at an increased risk. Patients receiving Meloxicam therapy may see an increased risk of a life-threatening allergic reaction (anaphylactoid reactions). This symptom worse typically in asthmatic patients who experience swelling of the nasal passages complicated by non-cancerous growth in the lining of the nose, fatal difficulty in breathing (bronchospasm), after taking aspirin or other NSAIDs
. Patients should take immediate medical attention if such symptoms occur. Inform the patients about the signs of a life-threatening allergic reaction such as difficulty breathing, swelling of the face or throat.
Pregnant women are at an increased risk when using this medicine. The use of Meloxicam during early pregnancy
may increase the risk of miscarriage
, defects of the abdominal wall and heart. Using Meloxicam during the third trimester of pregnancy may increase the harmful effect of the heart (high blood pressure or premature closure of the ductus arteriosus) and kidney failure with deficiency of amniotic fluid in the fetus (oligohydramnios
). At the end of pregnancy, Meloxicam may also cause inhibition of uterine contractions in pregnant mother which can lead to delayed or prolonged labour and prolongation of bleeding
time in mother and baby. This medicine should not be used in the third trimester of pregnancy.
Patients with kidney disease, using non-steroidal anti-inflammatory drugs for long-term or dehydrated patients are at increased risk. Kidney inflammation (interstitial nephritis
), swelling of the tiny filters in the kidneys (glomerulonephritis
), kidney cell damage, or excretion of too much protein in the urine (nephrotic syndrome
) may occur in patients using non-steroidal anti-inflammatory drugs. Patients with abnormal functioning of the kidney or liver, kidney failure, volume depletion, too much protein in the urine (nephrotic syndrome), inflammation of the kidney (lupus
nephropathy), heart failure, liver dysfunction, taking angiotensin-converting enzyme inhibitors, diuretics
, or angiotensin II receptor antagonists, and elderly patients are at higher risk of this reaction. Non-steroidal anti-inflammatory drug therapy should not be used in patients with kidney failure or increased levels of the kidney parameters. It is advised first to rehydrate the patients and then to initiate the therapy with # NAME#. Caution and monitoring should also be considered in patients with abnormal functioning of the kidney and kidney disease.
Heart failure, high blood pressure, or swelling of the skin
Patients with fluid retention, high blood pressure, cardiac failure, or swelling of the skin, taking Meloxicam, antihypertensive medicines (angiotensin-converting enzyme inhibitors, thiazides, loop diuretics
), are at increased risk. Such patients may experience an increased risk of heart disease events. Also, induction of potassium
and water retention may occur while taking non-steroidal anti-inflammatory drugs. Precaution and monitoring should be considered in such patients. In patients with high blood pressure, close monitoring of the high blood pressure should be done while starting and during non-steroidal anti-inflammatory drugs therapy.
Patients taking Meloxicam are at increased risk. Such patients may experience jaundice
, fatal swelling of the liver, liver cell damage (liver necrosis), liver failure, and increased level of liver enzymes. Patients with abnormal liver test or with signs and symptoms of an abnormality in the functioning of the liver should be examined for more severe liver reaction while on Meloxicam therapy. Dose modification is not required in patients with an abnormality in the functioning of the liver. Take necessary precautions while using Meloxicam in such patients.
Bleeding, ulcers, or rupture in the wall of the stomach and intestinal tract
Patients with a history of stomach or intestinal bleeding
disease, or a rupture in the wall of the digestive tract are at an increased risk. Such patients are at ten-fold greater risk for developing stomach and intestinal tract bleeding. Take necessary precautions while using Meloxicam with protective agents (proton pump inhibitors or misoprostol) in these patients. A lowest effective dose of Meloxicam for a short period should be used in such patients.
Patients with a recent history of heart bypass surgery (coronary artery bypass graft or CABG)
Patients with a recent history of heart bypass surgery
are at an increased risk when using this medicine. Such patients are at an increased risk of heart attack and stroke
when taking cyclooxygenase- 2 selective nonsteroidal anti-inflammatory drugs within the first 10 to 14 days following heart surgery. Meloxicam therapy should not be used in such patients.
Heart-related blood clotting problems
Patients taking Meloxicam and non-steroidal anti-inflammatory drugs therapy for more than three years are at an increased risk. These patients are at increased risk of heart and blood vessels disorders such as heart attack and stroke
, which can be possibly fatal. Patients with heart disease are at higher risk. The lowest effective dose for a short period should be used in such patients. Patients should be notified about the symptoms of heart disease events and essential measures to take if symptoms occur.
Serious skin reactions
Patients on Meloxicam therapy are at an increased risk. Patients using Meloxicam may experience serious skin adverse events such as life-threatening skin reaction (Stevens-Johnson Syndrome
), redness and peeling of the skin (exfoliative dermatitis
) and life-threatening drug-induced skin reaction, which can be fatal. Inform the patients about the symptoms of skin rash, fever
, or other signs of allergic reaction such as itching
. The Meloxicam should not be used at the first occurrence of skin rash and any other sign of allergic reaction.
Patients on long-term corticosteroid therapy
Discontinuation of corticosteroids
may lead to worsening of corticosteroid insufficiency. Patients should discontinue corticosteroids slowly when discontinuation of corticosteroids is necessary.
Masking of inflammation and fever
The use of Meloxicam in patients with complications of presumed painful and noninfectious conditions may reduce the utility of diagnostic sign of fever
Patients with blood vessel related heart and brain disease
Patients with high blood pressure, heart failure, heart disease, narrowing of blood vessels leading to reduced blood flow to the limbs (peripheral arterial disease) and blood vessel related brain disease (cerebrovascular disease) are at an increased risk when using this medicine. Using Meloxicam in these patients may cause fluid retention and excessive fluid build up in the body. When non-steroidal anti-inflammatory drugs are used at high doses for the long term, it may increase the risk of heart attack and stroke
. Proper monitoring of blood pressure should be done while starting Meloxicam therapy in such patients. Careful consideration should also be made in patients with risk factors such as high blood pressure, smoking
, high blood sugar, or high levels of fat particles in the blood before starting long-term treatment with Meloxicam.
Patients with long-term treatment of Meloxicam
Patients with long-term treatment of Meloxicam are at an increased risk. Long-term use of Meloxicam may cause severe stomach or intestinal ulcerations and bleeding
. The Meloxicam should not be used, if systemic events such as increased number of white blood cell (eosinophilia
) or rash occur if clinical symptoms of liver disease develop and if abnormal liver function tests worsen or persist.